AGIO News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AG

Mkt Cap

$1.87B

Volume

650.38K

Next Earnings

October 29th

Loading chart

AG

AGIOAgios Pharmaceuticals, Inc.

AGIO

Pay with—

Available Balance0.00

AG

Mkt Cap

$1.93B

Volume

650.38K

Next Earnings

October 29th

Chart Financials Earnings News About Insider Filings

Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock?Danaher Corporation is expected to report Q3 2026 revenues of $26.3 billion, up 8.2% year-over-year, driven by strength in Biotechnology, Diagnostics, and Life Sciences segments, plus the Masimo acquisition. However, rising input costs, product mix changes, and currency headwinds may pressure profits. The company has a positive Earnings ESP of +0.30% and Zacks Rank of 2 (Buy).Zacks Investment Research · Oct 16, 2026

4 High-Risk Stocks Built for Big ReturnsThe article highlights four high-risk, high-reward stocks: Agios Pharmaceuticals awaiting FDA approval for mitapivat to treat sickle cell disease; Navitas Semiconductor pivoting toward AI data centers and high-power chips; Joby Aviation developing eVTOL transportation services with autonomous capabilities; and Viking Therapeutics developing obesity drug VK2735 with potential in a multi-billion dollar market. All require patience but offer significant upside if their respective catalysts materialize.The Motley Fool · Oct 14, 2026

AGIO Stock Sinks 29% in Three Months: Here's What You Need to KnowAgios Pharmaceuticals' stock declined 29% over three months following the discontinuation of tebapivat across all indications after failing to demonstrate differentiation from existing treatments. With tebapivat no longer advancing, the company is increasingly dependent on mitapivat, which showed strong 259.3% year-over-year sales growth to $44.7 million in Q2 2026. However, intensifying competition from Novo Nordisk's etavopivat in the sickle cell disease market poses challenges as Agios awaits FDA approval for mitapivat in SCD by November 2026.Zacks Investment Research · Oct 6, 2026

Agios' Growth Story Hinges on Mitapivat's Commercial ExpansionAgios Pharmaceuticals' mitapivat-based drugs (Pyrukynd and Aqvesme) generated $44.7 million in Q2 2026 revenue, up 259% year-over-year, driven by early thalassemia adoption. However, the discontinuation of pipeline drug tebapivat and intensifying competition from Novo Nordisk's etavopivat in sickle cell disease have made the company heavily dependent on mitapivat's commercial success.Zacks Investment Research · Oct 2, 2026

As Sickle Cell Innovation Accelerates, Hematologists Signal Demand for a Broader Treatment Arsenal Beyond Gene TherapyHematologists increasingly favor a diverse sickle cell disease treatment landscape combining gene therapies with oral disease-modifying agents. Mitapivat (Agios) surged to the most desired pipeline therapy at 24% physician preference, while BEAM-101 (Beam Therapeutics) and etavopivat (Novo Nordisk) also gained traction. Despite innovation, 70% of hematologists rate unmet need as high, with 51% of SCD patients not optimally managed with current treatments.GlobeNewswire Inc. · Aug 25, 2026

Here's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related)Agios Pharmaceuticals stock surged over 14% after the FDA accepted its supplemental New Drug Application for mitapivat for sickle cell disease with Priority Review status and set a decision goal date of November 1. While the drug failed to meet its primary endpoint for reducing sickle cell pain crises, the FDA's accelerated approval pathway indicates confidence in the submitted data. Full traditional approval remains contingent on a confirmatory Phase 3 trial expected next year.The Motley Fool · Jul 7, 2026

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell DiseaseAgios presented detailed Phase 3 RISE UP trial results for mitapivat, an oral pyruvate kinase activator for sickle cell disease. The drug demonstrated statistically significant hemoglobin response improvement versus placebo with rapid onset and durable effects, clinically meaningful reduction in transfusion burden (41.1% relative reduction in patients requiring transfusions), and improvements in pain crises, fatigue, and quality of life measures among hemoglobin responders. Mitapivat was well-tolerated with a safety profile consistent with previous trials.GlobeNewswire Inc. · Jun 13, 2026

Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic SyndromesAgios Pharmaceuticals announced it will not advance tebapivat, a pyruvate kinase activator, in lower-risk myelodysplastic syndromes (LR-MDS) after Phase 2b trial results failed to meet predefined efficacy thresholds. While the drug was well-tolerated with no safety concerns, clinical benefit was insufficient in patient populations tested. The company will continue development of tebapivat in sickle cell disease with Phase 2 data expected in the second half of 2026.GlobeNewswire Inc. · May 29, 2026

Why Agios Pharmaceuticals Stock Zoomed to a 13% Gain on WednesdayAgios Pharmaceuticals stock surged 13% after reporting Q1 2026 earnings that beat analyst expectations. The company's lead drug mitapivat, marketed as Aqvesme and Pyrukynd, generated $20.7 million in revenue, up from $8.7 million year-over-year. The company plans to submit a supplemental FDA application for mitapivat in sickle cell disease treatment this quarter.The Motley Fool · Apr 29, 2026

Here's Why Agios Pharmaceuticals Crashed 23% TodayAgios Pharmaceuticals stock plummeted 23% after Novo Nordisk announced superior trial results for its sickle cell treatment etavopivat compared to Agios' mitapavit. Novo's drug met both primary endpoints and demonstrated statistically significant reduction in vaso-occlusive crises, while Agios' mitapavit failed to meet its primary endpoint. With Novo planning FDA approval filing in late 2026, Agios faces a longer and more uncertain path to market approval, significantly diminishing its mitapavit's commercial potential.The Motley Fool · Apr 20, 2026

to start trading

AG

AGIOAgios Pharmaceuticals, Inc.

AGIO

Pay with—

Available Balance0.00

Your PositionYou don't own any AGIO yet.

Related Tickers

Earnings